Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?

Clin Genitourin Cancer. 2013 Dec;11(4):e10-4. doi: 10.1016/j.clgc.2013.04.021. Epub 2013 Jun 27.

Authors

Orazio Caffo¹, Antonio Palermo, Antonello Veccia, Francesca Maines, Franca Chierichetti, Enzo Galligioni

Affiliation

¹ Medical Oncology Department, Santa Chiara Hospital, Trento, Italy. Electronic address: orazio.caffo@apss.tn.it.

PMID: 23810439
DOI: 10.1016/j.clgc.2013.04.021

No abstract available

Keywords: Abiraterone; Castration resistant prostate cancer; Choline positron emission tomography; Withdrawal response.

Publication types

Case Reports

MeSH terms

Abiraterone Acetate
Aged
Androstadienes / therapeutic use*
Drug Resistance, Neoplasm
Humans
Male
Positron-Emission Tomography
Prostate-Specific Antigen / blood*
Prostatic Neoplasms, Castration-Resistant / diagnostic imaging
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Steroid 17-alpha-Hydroxylase / antagonists & inhibitors
Substance Withdrawal Syndrome / metabolism*
Tomography, X-Ray Computed
Treatment Failure

Substances

Androstadienes
Steroid 17-alpha-Hydroxylase
Prostate-Specific Antigen
Abiraterone Acetate